{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T07:03:12Z","timestamp":1781247792432,"version":"3.54.1"},"reference-count":22,"publisher":"American Diabetes Association","issue":"6","license":[{"start":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T00:00:00Z","timestamp":1630108800000},"content-version":"vor","delay-in-days":2667,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,6,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>Plasma adiponectin levels are reduced in type 2 diabetes mellitus (T2DM) and other insulin-resistant states. We examined whether plasma adiponectin levels at baseline and after pioglitazone treatment in impaired glucose tolerance (IGT) subjects were associated with improved insulin sensitivity (SI) and glucose tolerance status.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>A total of 602 high-risk IGT subjects in ACT NOW were randomized to receive pioglitazone or placebo with a median follow-up of 2.4 years.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Pioglitazone reduced IGT conversion to diabetes by 72% in association with improved \u03b2-cell function by 64% (insulin secretion\/insulin resistance index) and increased tissue sensitivity by 88% (Matsuda index). In pioglitazone-treated subjects, plasma adiponectin concentration increased threefold from 13 \u00b1 0.5 to 38 \u00b1 2.5 \u03bcg\/mL (P &amp;lt; 0.001) and was strongly correlated with the improvement in SI (r = 0.436, P &amp;lt; 0.001) and modestly correlated with glucose area under the curve during oral glucose tolerance test (r = 0.238, P &amp;lt; 0.005) and insulin secretion\/insulin resistance index (r = 0.306, P &amp;lt; 0.005). The increase in adiponectin was a strong predictor of reversion to normal glucose tolerance and prevention of T2DM. In the placebo group, plasma adiponectin did not change and was not correlated with changes in glucose levels. There was an inverse association between baseline plasma adiponectin concentration and progression to diabetes in the placebo group but not in the pioglitazone group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Baseline adiponectin does not predict the response to pioglitazone. The increase in plasma adiponectin concentration after pioglitazone therapy in IGT subjects is strongly related to improved glucose tolerance status and enhanced tissue sensitivity to insulin.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc13-1745","type":"journal-article","created":{"date-parts":[[2014,4,5]],"date-time":"2014-04-05T03:06:18Z","timestamp":1396667178000},"page":"1706-1711","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":10,"title":["Baseline Adiponectin Levels Do Not Influence the Response to Pioglitazone in ACT NOW"],"prefix":"10.2337","volume":"37","author":[{"given":"Devjit","family":"Tripathy","sequence":"first","affiliation":[{"name":"Texas Diabetes Institute and University of Texas Health Science Center and Audie L. Murphy Hospital, South Texas VA Health Care System, San Antonio, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen C.","family":"Clement","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Georgetown University, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn C.","family":"Schwenke","sequence":"additional","affiliation":[{"name":"Phoenix VA Health Care System, Phoenix, AZ"},{"name":"College of Nursing and Health Innovation, Arizona State University, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MaryAnn","family":"Banerji","sequence":"additional","affiliation":[{"name":"State University of New York Health Science Center at Brooklyn, Brooklyn, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George A.","family":"Bray","sequence":"additional","affiliation":[{"name":"Pennington Biomedical Research Center\/Louisiana State University, Baton Rouge, LA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Buchanan","sequence":"additional","affiliation":[{"name":"University of Southern California Keck School of Medicine, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalia","family":"Gastaldelli","sequence":"additional","affiliation":[{"name":"University of Texas Health Science Center, San Antonio, TX, and Cardiometabolic Risk Unit, Institute of Clinical Physiology, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert R.","family":"Henry","sequence":"additional","affiliation":[{"name":"VA San Diego Healthcare System and University of California, San Diego, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbas E.","family":"Kitabchi","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, University of Tennessee, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunder","family":"Mudaliar","sequence":"additional","affiliation":[{"name":"VA San Diego Healthcare System and University of California, San Diego, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Ratner","sequence":"additional","affiliation":[{"name":"Medstar Research Institute, Hyattsville, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frankie B.","family":"Stentz","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, University of Tennessee, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Musi","sequence":"additional","affiliation":[{"name":"Texas Diabetes Institute and University of Texas Health Science Center and Audie L. Murphy Hospital, South Texas VA Health Care System, San Antonio, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter D.","family":"Reaven","sequence":"additional","affiliation":[{"name":"Phoenix VA Health Care System, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph A.","family":"DeFronzo","sequence":"additional","affiliation":[{"name":"Texas Diabetes Institute and University of Texas Health Science Center and Audie L. Murphy Hospital, South Texas VA Health Care System, San Antonio, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2014,5,10]]},"reference":[{"key":"2022031219431415900_B1","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.2337\/dc12-2563","article-title":"Secular changes in U.S. Prediabetes prevalence defined by hemoglobin A1c and fasting plasma glucose: National Health and Nutrition Examination Surveys, 1999-2010","volume":"36","author":"Bullard","year":"2013","journal-title":"Diabetes Care"},{"key":"2022031219431415900_B2","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1007\/s00125-012-2598-x","article-title":"Adiponectin: mechanistic insights and clinical implications","volume":"55","author":"Turer","year":"2012","journal-title":"Diabetologia"},{"key":"2022031219431415900_B3","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1042\/CS20010336","article-title":"Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population","volume":"103","author":"Yamamoto","year":"2002","journal-title":"Clin Sci (Lond)"},{"key":"2022031219431415900_B4","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.cmet.2006.05.002","article-title":"Role of adiponectin in human skeletal muscle bioenergetics","volume":"4","author":"Civitarese","year":"2006","journal-title":"Cell Metab"},{"key":"2022031219431415900_B5","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2337\/diacare.27.2.629","article-title":"Exercise increases adiponectin levels and insulin sensitivity in humans","volume":"27","author":"Kriketos","year":"2004","journal-title":"Diabetes Care"},{"key":"2022031219431415900_B6","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.2337\/diabetes.53.6.1621","article-title":"Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes","volume":"53","author":"Tonelli","year":"2004","journal-title":"Diabetes"},{"key":"2022031219431415900_B7","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nature01705","article-title":"Cloning of adiponectin receptors that mediate antidiabetic metabolic effects","volume":"423","author":"Yamauchi","year":"2003","journal-title":"Nature"},{"key":"2022031219431415900_B8","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/nature08991","article-title":"Adiponectin and AdipoR1 regulate PGC-1alpha and mitochondria by Ca(2+) and AMPK\/SIRT1","volume":"464","author":"Iwabu","year":"2010","journal-title":"Nature"},{"key":"2022031219431415900_B9","doi-asserted-by":"crossref","first-page":"25863","DOI":"10.1074\/jbc.C200251200","article-title":"Disruption of adiponectin causes insulin resistance and neointimal formation","volume":"277","author":"Kubota","year":"2002","journal-title":"J Biol Chem"},{"key":"2022031219431415900_B10","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nm724","article-title":"Diet-induced insulin resistance in mice lacking adiponectin\/ACRP30","volume":"8","author":"Maeda","year":"2002","journal-title":"Nat Med"},{"key":"2022031219431415900_B11","doi-asserted-by":"crossref","first-page":"980","DOI":"10.2337\/db07-1419","article-title":"Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program","volume":"57","author":"Mather","year":"2008","journal-title":"Diabetes"},{"key":"2022031219431415900_B12","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.1210\/jc.2004-0190","article-title":"Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients","volume":"89","author":"Miyazaki","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031219431415900_B13","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s00125-007-0698-9","article-title":"Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus","volume":"50","author":"Bajaj","year":"2007","journal-title":"Diabetologia"},{"key":"2022031219431415900_B14","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa1010949","article-title":"Pioglitazone for diabetes prevention in impaired glucose tolerance","volume":"364","author":"DeFronzo","year":"2011","journal-title":"N Engl J Med"},{"key":"2022031219431415900_B15","doi-asserted-by":"crossref","first-page":"362","DOI":"10.2337\/diab.35.3.362","article-title":"The insulin sensitivity index in nondiabetic man. Correlation between clamp-derived and IVGTT-derived values","volume":"35","author":"Beard","year":"1986","journal-title":"Diabetes"},{"key":"2022031219431415900_B16","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N Engl J Med"},{"key":"2022031219431415900_B17","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.2337\/diabetes.50.9.2094","article-title":"PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein","volume":"50","author":"Maeda","year":"2001","journal-title":"Diabetes"},{"key":"2022031219431415900_B18","doi-asserted-by":"crossref","first-page":"E42","DOI":"10.1152\/ajpendo.00240.2005","article-title":"Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression","volume":"290","author":"Rasouli","year":"2006","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2022031219431415900_B19","doi-asserted-by":"crossref","first-page":"E480","DOI":"10.1152\/ajpendo.90892.2008","article-title":"Adiponectin translation is increased by the PPARgamma agonists pioglitazone and omega-3 fatty acids","volume":"296","author":"Banga","year":"2009","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2022031219431415900_B20","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2337\/db09-9028","article-title":"Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus","volume":"58","author":"Defronzo","year":"2009","journal-title":"Diabetes"},{"key":"2022031219431415900_B21","doi-asserted-by":"crossref","first-page":"16309","DOI":"10.1073\/pnas.222657499","article-title":"Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation","volume":"99","author":"Tomas","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022031219431415900_B22","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/nm788","article-title":"Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase","volume":"8","author":"Yamauchi","year":"2002","journal-title":"Nat Med"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/37\/6\/1706\/621638\/1706.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/37\/6\/1706\/621638\/1706.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T21:25:02Z","timestamp":1647120302000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/37\/6\/1706\/30009\/Baseline-Adiponectin-Levels-Do-Not-Influence-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,10]]},"references-count":22,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2014,5,10]]},"published-print":{"date-parts":[[2014,6,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc13-1745","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,10]]}}}